1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Qiagen N.V.
  6. Summary
    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
Delayed Nyse  -  04:00 2022-07-05 pm EDT
48.32 USD   +0.98%
06/30QIAGEN N : 2021 GRI Annex
PU
06/24QIAGEN N.V.(NYSE : QGEN) dropped from Russell 1000 Value-Defensive Index
CI
06/24QIAGEN N.V.(NYSE : QGEN) dropped from Russell 1000 Defensive Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
46.83(c) 46.68(c) 47.2(c) 47.85(c) 48.32 Last
771 657 1 295 103 1 189 482 1 352 569 1 319 738 Volume
-0.34% -0.32% +1.11% +1.38% +0.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2 093 M - -
Net income 2022 387 M - -
Net Debt 2022 497 M - -
P/E ratio 2022 28,3x
Yield 2022 -
Sales 2023 2 154 M - -
Net income 2023 427 M - -
Net Debt 2023 95,5 M - -
P/E ratio 2023 25,5x
Yield 2023 -
Capitalization 10 990 M 10 990 M -
EV / Sales 2022 5,49x
EV / Sales 2023 5,15x
Nbr of Employees 6 000
Free-Float 98,2%
More Financials
Company
Qiagen N.V. is one of the world's leaders in designing, manufacturing, and marketing chemical products for the isolation, purification, and manipulation of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). In 2021, the group developed more than 500 core consumable products and automated solutions through its over 35 locations worldwide. Net sales break down geographically as follows: Europe/Middle... 
More about the company
Ratings of Qiagen N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about QIAGEN N.V.
06/30QIAGEN N : 2021 GRI Annex
PU
06/24QIAGEN N.V.(NYSE : QGEN) dropped from Russell 1000 Value-Defensive Index
CI
06/24QIAGEN N.V.(NYSE : QGEN) dropped from Russell 1000 Defensive Index
CI
06/23Qiagen N.V. Appoints Eva Pisa as New Supervisory Board Member
CI
06/23Qiagen N.V. to Seek M&A
CI
06/23TRANSCRIPT : Qiagen N.V. - Shareholder/Analyst Call
CI
06/17TCS Partners with QIAGEN in Driving its Cloud Transformation Strategy
AQ
06/16Tata Consultancy Services Bags New Contract from Germany's QIAGEN
MT
06/10QIAGEN N.V. : Notification and public disclosure of transactions by persons
EQ
06/08QIAGEN NV : Jefferies reaffirms its Neutral rating
MD
06/08TRANSCRIPT : QIAGEN N.V. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2..
CI
06/03Test makers target monkeypox market as cases surge
RE
06/01U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infe..
BU
05/26QIAGEN NV : Gets a Buy rating from Deutsche Bank
MD
05/24TRANSCRIPT : QIAGEN N.V. Presents at UBS Global Healthcare Conference, May-24-2022 10:45 A..
CI
More news
News in other languages on QIAGEN N.V.
06/24AKTIEN FRANKFURT : Dax klettert wieder über 13 000 Punkte
06/24AKTIEN FRANKFURT : Dax testet Hürde bei 13000 Punkten - Zalando brechen ein
06/23Qiagen N.V. nomme Eva Pisa comme nouveau membre du conseil de surveillance
06/23Qiagen N.V. cherche à réaliser des fusions et acquisitions
06/21MÄRKTE EUROPA/Marktbreite stimmt - aber DAX bleibt zurück
More news
Analyst Recommendations on QIAGEN N.V.
More recommendations
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 48,32 $
Average target price 56,32 $
Spread / Average Target 16,6%
EPS Revisions
Managers and Directors
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Vice President-Finance
Lawrence A. Rosen Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Lezette Young Manager-Compliance & Legal
Sector and Competitors
1st jan.Capi. (M$)
QIAGEN N.V.-13.06%10 884
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-7.58%19 151